Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Endostar Combined With AI Regimen Compared With AI Regimen in Adjuvant Treatment After Radical Resection of Recurrent Soft Tissue Sarcoma

NCT04699214 is registered in ClinicalTrials.gov with Yong Chen as lead sponsor.

NCT NCT04699214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04699214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Endostar Combined With AI Regimen Compared With AI Regimen in Adjuvant Treatment After Radical Resection of Recurrent Soft Tissue Sarcoma
Lead sponsor
Yong Chen
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2020
Completion date
August 31, 2023
Enrollment
210 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

other disorders of soft tissues